Mental Illness

Creatine Supplements Show Early Promise for Boosting Brain Energy in Alzheimer's Patients

A recent pilot study provides encouraging insights into the potential of a common dietary supplement, creatine, for enhancing brain health in individuals grappling with Alzheimer's disease. The research indicates that participants who consistently consumed creatine monohydrate over an eight-week period experienced a measurable uptick in brain energy and noticeable improvements in cognitive function. This groundbreaking work suggests an alternative therapeutic strategy that centers on revitalizing the brain's metabolic processes, which are often compromised in Alzheimer's patients.

Creatine Offers Hope for Alzheimer's Brain Health

In a pioneering pilot study, researchers from the University of Kansas Medical Center, including Aaron N. Smith and Matthew K. Taylor, investigated the impact of creatine monohydrate on Alzheimer's patients. Published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, their findings offer a glimmer of hope for a novel approach to managing the disease. Twenty older adults, aged 60 to 90, all clinically diagnosed with progressive dementia due to Alzheimer's, participated in the eight-week trial. To ensure the study's relevance, participants' blood was analyzed for the p-tau217 biomarker, confirming a high likelihood of true Alzheimer's pathology, and nearly two-thirds carried the APOE gene variant linked to late-onset Alzheimer's.

Participants were instructed to take 20 grams of creatine monohydrate daily, split into two 10-gram doses, dissolved in a beverage. Study partners meticulously tracked daily consumption. Blood samples, drawn at the beginning, middle, and end of the trial, confirmed elevated creatine levels, indicating successful absorption. Magnetic resonance spectroscopy, an advanced brain scanning technique, revealed an average 11% increase in total brain creatine levels in the frontal and parietal regions, confirming that the supplement successfully crossed the blood-brain barrier and integrated into the brain's energy storage systems.

Remarkably, the study revealed early cognitive benefits. Participants' overall cognitive test scores improved by approximately three points. They showed enhanced fluid cognition, which involves problem-solving and rapid information processing, and better performance on working memory tasks. Oral reading recognition scores also increased, as did the ability to focus amidst distractions. The degree of improvement in reading performance correlated with the increase in brain creatine levels. The supplement proved to be highly feasible and well-tolerated, with 19 out of 20 participants completing at least 80% of the daily doses. Minor side effects, such as temporary muscle cramping, occasional diarrhea, or disrupted sleep, were largely self-resolving, and metabolic blood tests showed no adverse impact on major organs.

This pilot study, while promising, acknowledges its limitations as a single-arm trial without a control group. Future larger-scale clinical trials with placebo controls and longer observation periods are essential to definitively confirm creatine's direct cognitive benefits and long-term efficacy. If these early findings are corroborated, this affordable and widely accessible supplement could become a valuable tool in supporting brain health and delaying cognitive decline in Alzheimer's disease.

This research underscores the potential of an accessible dietary supplement to address a critical aspect of Alzheimer's pathology: energy dysfunction. By targeting brain metabolism, creatine may offer a complementary strategy to existing treatments that primarily focus on plaque reduction. The study's emphasis on practicality, safety, and measurable cognitive improvements provides a compelling foundation for future investigations into creatine's role in neurodegenerative diseases. As we continue to seek effective interventions for Alzheimer's, metabolic support through compounds like creatine could offer a tangible path towards improving patients' quality of life and prolonging independent function.

Bridging Altered States: Psychedelics, Madness, and the Quest for Integrated Healing

This article explores a personal journey through altered states, traditional psychiatric approaches, and the eventual discovery of psychedelic-assisted therapy (PAT) as a path to profound healing and integration. It highlights the challenges faced by individuals navigating mental health systems and advocates for a more nuanced and compassionate approach to understanding and treating complex mental experiences.

Unveiling the Spectrum: From Madness to Meaning Through Psychedelics

The Long Shadow of a Crisis: Navigating the Aftermath of Psychosis

The author recounts the arduous process of recovering from a life-altering crisis in 1990, a period diagnosed as psychosis. This experience involved a terrifying descent into a "pan-dimensional hellscape" filled with distressing imagery and voices, leaving a lasting impact on her life. The resistance to conventional medication, which she felt would erode her true self, further complicated her journey.

A Lingering Desire for Transcendence: Beyond the Veil of Consensus Reality

Despite the horrors of her psychotic episode, the author yearned for the rare moments of profound clarity and spiritual awareness she had occasionally experienced. These transcendent states offered exquisite insights and a sense of unity, free from pain, doubt, or shame. This longing persisted even as she strived to integrate back into everyday life and reconnect with her children, who were her primary motivation for recovery.

Embracing New Pathways: The Unexpected Turn Towards Psychedelic Therapy

Initially hesitant due to a fragile psyche, the author's perspective on psychedelics shifted in late 2021. Repeated encounters with literature and personal testimonies about psychedelic therapy sparked a cautious curiosity. The idea of carefully guided psilocybin use, coupled with professional preparation and integration, emerged as a potential avenue for healing unresolved aspects of her past and recapturing some of the spiritual understanding she had known.

The Transformative Power of Psychedelic Integration: A Journey of Healing and Balance

After 18 months of consistent therapeutic sessions, the author underwent a psilocybin experience. While not inherently pleasurable, the session, conducted in a safe environment with experienced companions, facilitated significant healing. Crucially, the subsequent integration process, diligently supported by her therapist, proved to be the most impactful. This led to a gentler, more manageable form of transcendence, fostering a newfound balance between the ordinary and the profound.

Challenging Conventional Wisdom: The Disconnect in Mental Health Approaches

The author reflects on the stark contrast between her personal experience of integrating psychedelic insights and the historical approach of mental health services to spontaneous altered states. She posits that integrating her 1990 experiences with the same care provided by PAT could have significantly reduced her suffering. However, she notes that such comprehensive healing remains largely inaccessible within both conventional psychiatry and current psychedelic research, particularly for those with a history of psychosis, who are often deemed too high-risk.

Re-evaluating Exclusion Criteria: A Call for Inclusive Psychedelic Research

The article critiques the widespread exclusion of individuals with psychotic disorders from psychedelic research, citing the severe and persistent challenges faced by this population, including reduced life expectancy and stagnant clinical improvement. While acknowledging that PAT may not be suitable for everyone, the author advocates for a reconsideration of these broad exclusion criteria, urging for more individualized and compassionate assessments.

Bridging the Divide: Integrating Experiences of Mysticism and Madness

The author highlights the distinct approaches to altered states in psychedelic research versus psychosis research. Psychedelic studies often explore experiences of mysticism and ego dissolution, utilizing tools like the Ego-Dissolution Inventory (EDI). In contrast, psychosis research primarily focuses on pathological symptoms. The author recounts how questions from the EDI would have been invaluable during her own "psychotic" experience, potentially validating her perceptions and fostering a sense of understanding rather than mere medication.

"Ask Us": A Poetic Plea for Empathy and Understanding

Years before her PAT journey, the author penned a poem, "Ask Us: To a Long-Ago Psychiatrist and Some Current Ones Too," expressing her desire for mental health professionals to explore the profound experiences underlying what is often labeled "lunacy." She emphasizes that the "fascinating territory" of her spontaneous altered states was far more meaningful than her subsequent psychedelic experience, yet received no curious inquiry, only a push towards medication.

Forging New Paths: The MadPsychedelics Collaboratory and Future Hopes

Inspired by her healing journey, the author has engaged with the growing field of psychedelic research and therapy, particularly at the intersection of psychedelics and psychosis. She is part of the MadPsychedelics Collaboratory, a collective aiming to empower individuals with lived experience to lead research in this area. The initiative seeks to ask more pertinent questions and analyze data without the fear or stigma often associated with pathologized non-ordinary states, ultimately hoping to transform mental health services and inform future psychedelic research through the lens of madness liberation movements.

See More

The Decline of Human Connection in Healthcare: Lessons from Bernard Lown's "The Lost Art of Healing"

This article delves into the profound observations of Dr. Bernard Lown, a distinguished cardiologist and Nobel Peace Prize recipient, whose book, "The Lost Art of Healing," critically examines the increasing depersonalization within the medical field. Lown posited that despite technological advancements, the essence of healing lies in robust human relationships—between doctors and patients, and among patients and their social networks. The author highlights how modern psychiatry has unfortunately mirrored this trend, often prioritizing symptom management through pharmaceuticals and technology over fostering deep, empathetic connections essential for emotional well-being. This shift, driven by economic pressures and a 'childish faith in the magic of technology,' has led to widespread patient dissatisfaction and a noticeable absence of genuine care, transforming healthcare into an industrialized, transactional service.

Bernard Lown, celebrated for inventing the direct-current defibrillator and pioneering lidocaine's use for heart arrhythmias, paradoxically expressed dismay at the dehumanizing consequences of technological over-reliance in medicine. His 1996 book, "The Lost Art of Healing," articulated his concern that technology had overshadowed patient care, leading to a focus on fragmented biological parts rather than the whole person. Lown's critique underscored two pivotal relationship areas for heart health: the physician-patient bond and the patient's connections with their family and social circles. He lamented that psychiatry, despite its mandate to address emotional struggles, has largely ignored or superficially engaged with these relational aspects, a point of contention with apologist psychiatrists like Awais Aftab, who defend the profession's pluralistic approach.

Aftab's defense, referencing George Engel's "Biopsychosocial Model" from 1980, is challenged by the contemporary reality of psychiatric practice. The New York Times reported in 2011 that only a small fraction of psychiatrists offered talk therapy, a number that has likely dwindled further. Today, most psychiatric encounters are reduced to brief "medication management" sessions, making truly healing, relationship-centric interactions exceptionally rare. Lown's own early interest in psychiatry waned due to this inherent depersonalization, foreseeing the very issues that now plague the field. He recognized that the industrialization of medicine, demanding product standardization and interchangeable parts, relegated human empathy, kindness, and suffering beyond the scope of scientific measurement and business efficiency.

Lown's book is rich with personal anecdotes illustrating the transformative power of genuine doctor-patient relationships. One striking example involves a Jewish patient suffering from recurrent atrial fibrillation, whose condition defied conventional drug treatments. Lown discovered that the patient's physical ailment was deeply intertwined with profound emotional distress stemming from estrangement from his daughter who had married a non-Jewish man. After an emotionally charged, albeit initially angry, confrontation, Lown urged the patient to seek forgiveness, leading to a reconciliation with his daughter and a remarkable resolution of his cardiac symptoms. This episode highlighted not only the critical role of emotional healing but also Lown's later self-reflection on the importance of compassionate persuasion over confrontational tactics, even when successful.

In another instance, Lown recounted his efforts with a 60-year-old man battling severe coronary artery disease. Despite multiple medical interventions, his angina persisted. Lown uncovered a deep-seated estrangement from his homosexual son. This time, Lown approached the issue with calm and gentle coaxing, challenging the patient's irrational prejudice. The patient reconnected with his son, found emotional peace, and became an advocate for gay rights, coincidently experiencing a significant improvement in his angina. These stories demonstrate Lown's core belief that profound human connection and emotional well-being are inextricably linked to physical health, a principle often overlooked in modern, technologically-driven medicine.

The economic landscape plays a significant role in the current state of psychiatry, where "talk doesn't pay." The 2011 New York Times article vividly described psychiatrists, like Dr. Donald Levin, reducing patient interactions to brief medication checks, sacrificing meaningful therapeutic engagement for financial viability. Levin's candid admission of training himself to disengage emotionally from patients reflects a system that undervalues the 'craft' of healing. This economic pressure, coupled with a focus on quantifiable 'symptoms' rather than holistic well-being, explains why many mental health professionals, including therapists, often offer what is perceived as superficial care. True healing, Lown argued, requires empathy, kindness, and a deep appreciation for the patient's uniqueness—qualities that defy the mechanistic, efficiency-driven model of industrialized medicine.

The article concludes by emphasizing that the erosion of meaningful relationships in healthcare extends beyond mere economics. It points to a broader systemic issue where professionals are trained as technicians, rather than healers, often lacking the talent and wisdom for profound therapeutic engagement. The inability to integrate 'love'—defined as deep affection, valuing, and respect for another's uniqueness—into professional practice creates an existential dilemma for many. This deficiency leads to widespread patient dissatisfaction and contributes to a growing rebellion against dehumanizing, industrialized medicine and psychiatry. As Lown predicted, patients ultimately seek a partnership with caregivers who address their 'aching souls' as much as their 'malfunctioning anatomy,' desiring a covenant of trust and caring that transcends mere business transactions. The Lown Institute today champions this vision, advocating for a health system that prioritizes healing, equity, and the clinician-patient relationship over profits.

See More